KACTUS’ AAV Titration ELISA Kits utilize monoclonal antibodies specific to individual serotypes for precise titration of intact AAV capsids. About...

KACTUS is thrilled to announce that our GMP-Grade Cas9 enzyme is playing a pivotal role in the development of Bioheng Therapeutics'...

Nucleic acid removal is an essential step in biologics production workflows. Our MaxNuclease™ enzyme is a non-specific endonuclease from Serratia...

The approval of Casgevy in the UK in December 2023, the first CRISPR gene editing drug, marked the era of...

November 14, 2024 Base Therapeutics announced that its independently developed NK510 cell injection, the world's first base-edited universal NK cell...

With the first CRISPR gene-editing drug approved for over ten months now, what exciting developments are there in CRISPR drug...

After successful IND approval this past July, we are excited to announce the NK therapy NK510 received clinical trial approval from...

In a groundbreaking development for the biotech industry, KACTUS's GMP-grade Cas9 has critically helped Yizun Bio secure IND clearance for a universal...

FDA Official Guidelines On January 31, 2024, the FDA CBER officially released the "Human Gene Therapy Products Incorporating Human Genome...

Since its debut in 2016, base editing technology has opened up new perspectives and methods for drug development with its...

Through decades of rapid development, gene editing technology has officially entered the CRISPR 2.0 era, with new technologies such as...

Overview By leveraging its sophisticated ‘Structure Aided Design and Multiplex Screening (SAMS™)’ platform, along with extensive experience in process development...